cilomilast has been researched along with sulfasalazine in 2 studies
| Studies (cilomilast) | Trials (cilomilast) | Recent Studies (post-2010) (cilomilast) | Studies (sulfasalazine) | Trials (sulfasalazine) | Recent Studies (post-2010) (sulfasalazine) |
|---|---|---|---|---|---|
| 162 | 13 | 42 | 4,437 | 585 | 938 |
| Protein | Taxonomy | cilomilast (IC50) | sulfasalazine (IC50) |
|---|---|---|---|
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | 1.5 | |
| Solute carrier organic anion transporter family member 2B1 | Homo sapiens (human) | 3 | |
| Carbonic anhydrase 1 | Homo sapiens (human) | 3.04 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 4.49 | |
| Mitogen-activated protein kinase 1 | Homo sapiens (human) | 6.332 | |
| Sodium/bile acid cotransporter | Homo sapiens (human) | 9.6 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 0.46 | |
| Cystine/glutamate transporter | Homo sapiens (human) | 0.16 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 0.56 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Balliano, TL; Barbosa, G; Carvalho, VF; da Silva, BA; de Souza, ET; Lima, LM; Martins, IRR; Martins, MA; Medeiros, MM; Moraes Junior, MO; Nunes, IKDC; Silva, PMR; Silva, SWD | 1 |
2 other study(ies) available for cilomilast and sulfasalazine
| Article | Year |
|---|---|
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.
Topics: Animals; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Design; Enzyme Inhibitors; Humans; Hydrazones; Hypersensitivity; Lung; Male; Mice | 2020 |